Business
Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019
CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn
About this update from Vericel Corporation
[{"type":"text","content":"CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO & VP of Corporate Development, will present the latest company overview at the Ladenburg Thalmann 2019 Healthcare Conference in New York on Tuesday, September 24, 2019 at 11:00am Eastern Time.\n A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company's website at www.vcel.com. Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2019 Vericel Corporation. All rights reserved. Global Media Contacts:David SchullRusso Partners [email protected]+1 212-845-4271 (office)+1 858-717-2310 (mobile) Karen ChaseRusso Partners [email protected]+1 646-942-5627 (office)+1 917-547-0434 (mobile) Investor Contacts:Chad RubinSolebury [email protected]+1 646-378-2947 Lee SternSolebury [email protected]+1 646-378-2922 \n\n\nSource: Vericel Corporation","length":4045,"tagName":"div"}]